|Videos|April 5, 2021

Building COVID-19 Vaccine Trust is a Two-Way Street

Vaccine access and new cases are both increasing. An expert discusses earning trust in at-risk communities.

A new research letter highlighting a San Francisco-based survey study highlighted concerning disparities in racial and ethnic likelihood of interest in getting a COVID-19 vaccine.

The findings, which come at a time when COVID-related inequity has been well-defined among differing races and ethnic groups in the US, highlight the historical systemic issue of healthcare inequality among patients.

Investigators reported that Asian and multiracial individuals, and those of other races were more similar to Black and Latinx individuals than White individuals in their likeliness of getting a COVID-19 vaccine.

As people of color and their respective US communities have faced disproportionate burden of the pandemic, inequities in vaccination, investigators wrote, would compound these disparities.

In a Contagion interview regarding these findings, study author Kevin Grumbach, MD, of the Department of Family and Community Medicine at University of California San Francisco, discussed the implication of results at a time when vaccination rollout is peaking in the US, and new cases are again steadily increasing.

“There’s been a really good framework to say we should really talk about our trustworthiness,” Grumbach said. “Have we earned the trust, as people in public health, biomedical research, and healthcare, particularly with communities that have been subject to oppression and even in exploitation in certain biomedical activities?”


Related to this article

Cefiderocol Continues to Show Activity Against Resistant Gram-Negative Infections
Shionogi data presented at IDWeek 2026 demonstrated a 76.7% clinical response with cefiderocol in carbapenem-resistant respiratory infections and high in vitro activity against resistant P aeruginosa VAP isolates. Christine Slover, PharmD, vice president, Infectious Diseases US Medical Affairs, Shionogi, offers insights on the data as well as clinical considerations for providers when weighing the antibiotic for patients.
Pfizer 25-Valent Pneumococcal Vaccine Boosts Serotype 3 Response in Infants
Alejandra Gurtman, MD, discussed the phase 2 data at IDWeek 2026 which showed the investigational 25-valent pneumococcal conjugate vaccine 25vPnC produced serotype 3 antibody levels about 15-fold higher than Prevnar 20 after the booster dose, targeting a serotype still behind 10.6% of invasive pneumococcal disease in US children younger than five years.
Household Contacts Drive Most Hepatitis B Exposures in Young Children
Karen B. Jacobson, MD, MPH, of Kaiser Permanente Northern California, presented data at IDWeek 2026 showing 58.2% of children younger than five years exposed to active hepatitis B in the home were exposed by someone other than their birth mother, a risk maternal screening alone would miss under the CDC’s revised birth dose recommendation.
Inhaled Amikacin Shows Low Resistance Rates in MAC Lung Disease in ENCORE
In the phase 3b ENCORE trial, adding amikacin liposome inhalation suspension (ALIS) to azithromycin and ethambutol significantly improved culture conversion in newly diagnosed MAC lung disease, while treatment-emergent amikacin (2.2%) and macrolide (1.1%) resistance stayed rare. Kevin Winthrop, MD, provides insights around the study.